<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328172</url>
  </required_header>
  <id_info>
    <org_study_id>1218.5</org_study_id>
    <nct_id>NCT00328172</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Five Parallel Group Study Investigating the Efficacy and Safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg Administered Orally Once Daily) Over 12 Weeks in Drug Naive and Treated Patients With Type 2 Diabetes With Insufficient Glycemic Control (Study Includes an Open-label Metformin Treatment Arm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the efficacy, safety and tolerability of
      several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of
      treatment in patients with Type 2 diabetes and insufficient glycemic control. In addition,
      there will be an open-label treatment arm with metformin for sensitivity measurement with
      this patient population. Population pharmacokinetics of BI 1356 BS will also be assessed in
      this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The change from baseline reflects the Week 12 HbA1c minus the Week 0 HbA1c. Means are adjusted for baseline HbA1c.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Change from baseline reflects the Week 12 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Absolute Efficacy Response (HbA1c &lt;= 7.0%) at 12 Weeks</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>An absolute efficacy response is defined as HbA1c &lt;= 7.0% at 12 weeks. A non-response is defined as HbA1c &gt; 7.0% at 12 weeks.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching BI 1356</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1356 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1356 dose 1 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1356 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1356 dose 2 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1356 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1356 dose 3 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 1356</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356 dose 3 once daily</intervention_name>
    <description>BI 1356 dose 3 once daily</description>
    <arm_group_label>BI 1356 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356 dose 2 once daily</intervention_name>
    <description>BI 1356 dose 2 once daily</description>
    <arm_group_label>BI 1356 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356 dose 1 once daily</intervention_name>
    <description>BI 1356 dose 1 once daily</description>
    <arm_group_label>BI 1356 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and female patients with a diagnosis of Type 2 diabetes treated only with diet
             and exercise (drug naïve) or with one or two oral hypoglycemic agents (as single
             treatment or in combination) other than rosiglitazone or pioglitazone -treatment.
             Antidiabetic therapy has to be stable for at least 10 weeks prior to screening.

          2. Diagnosis of Type 2 diabetes with duration of at least 3 months

          3. Glycosylated haemoglobin A1 (HbA1c) of:

             7.5-10.0% at screening for drug naïve patients (no wash-out needed) 7.0-9.0% at
             screening for patients treated with only one oral antidiabetic agent (wash-out
             required) 6.5-8.0% at screening for patients treated with two oral antidiabetic agents
             (wash-out required)

          4. HbA1c of 7.5%-10.0% at Visit 3 (beginning of the 2-week placebo run-in period).

          5. Age &gt;=21 and &lt;=75 years.

          6. BMI (Body Mass Index) &gt;=25.0 and &lt;=40 kg/m2.

          7. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and local legislation

        Exclusion criteria:

          1. Clinically relevant cardiovascular disease (e.g., myocardial infarction, stroke or
             transient ischemic attack within six months before enrollment)

          2. Impaired hepatic function defined by serum levels of either alanine aminotransferase,
             aspartate aminotransferase or alkaline phosphatase above 3-fold upper limit of normal

          3. Renal insufficiency or impaired renal function defined by serum creatinine above upper
             limit of normal at screening

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             clinically relevant neurologic disorders (including cerebrovascular but with the
             exception of polyneuropathy) that would interfere with participation in the trial

          5. Chronic or clinically relevant acute infections (e.g., Human immunodeficiency virus,
             Hepatitis)

          6. History of relevant allergy/hypersensitivity that would interfere with trial
             participation (including allergy to investigational product or its excipients)

          7. Treatment with rosiglitazone or pioglitazone within 6 months prior to screening

          8. Treatment with insulin within 3 months prior to screening

          9. Alcohol or drug abuse within the last 3 months that would interfere with trial
             participation)

         10. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         11. Fasting plasma glucose &gt;240 mg/dl (= 13.3 mmol/L) at Visit 2, 3 or 4 any visit and
             confirmed by a second measurement (not on the same day)

         12. Pre-menopausal women (last menstruation &lt;=1 year prior to signing informed consent)
             who:

               1. are not surgically sterile,

               2. or are nursing or pregnant;

               3. or are of child-bearing potential and are not practicing an acceptable method of
                  birth control, or do not plan to continue using this method throughout the study
                  and do not agree to submit to periodic pregnancy testing during participation in
                  the trial. Acceptable methods of birth control include transdermal patch,
                  intra-uterine devices, oral, implantable or injectable contraceptives and
                  vasectomised partner. No exception will be made.

         13. Intolerance of metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.5.10020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.10014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miranda</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.61005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.61006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dandenong</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.61007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Ringwood</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montague</city>
        <state>Prince Edward Island</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.11018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olomouc 9</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 9</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sternberk</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.5.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2006</study_first_submitted>
  <study_first_submitted_qc>May 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2006</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>May 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2011</results_first_posted>
  <last_update_submitted>February 15, 2014</last_update_submitted>
  <last_update_submitted_qc>February 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients randomized to receive treatment with matching placebo</description>
        </group>
        <group group_id="P2">
          <title>Linagliptin (BI 1356) 0.5 mg</title>
          <description>Patients randomized to receive treatment with linagliptin 0.5 mg</description>
        </group>
        <group group_id="P3">
          <title>Linagliptin (BI 1356) 2.5 mg</title>
          <description>Patients randomized to receive treatment with linagliptin 2.5 mg</description>
        </group>
        <group group_id="P4">
          <title>Linagliptin (BI 1356) 5.0 mg</title>
          <description>Patients randomized to receive treatment with linagliptin 5.0 mg</description>
        </group>
        <group group_id="P5">
          <title>Metformin</title>
          <description>Patients randomized to receive treatment with metformin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients randomized to receive treatment with matching placebo</description>
        </group>
        <group group_id="B2">
          <title>Linagliptin (BI 1356) 0.5 mg</title>
          <description>Patients randomized to receive treatment with linagliptin 0.5 mg</description>
        </group>
        <group group_id="B3">
          <title>Linagliptin (BI 1356) 2.5 mg</title>
          <description>Patients randomized to receive treatment with linagliptin 2.5 mg</description>
        </group>
        <group group_id="B4">
          <title>Linagliptin (BI 1356) 5.0 mg</title>
          <description>Patients randomized to receive treatment with linagliptin 5.0 mg</description>
        </group>
        <group group_id="B5">
          <title>Metformin</title>
          <description>Patients randomized to receive treatment with metformin</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="65"/>
            <count group_id="B6" value="302"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="8.9"/>
                    <measurement group_id="B2" value="58.0" spread="9.4"/>
                    <measurement group_id="B3" value="59.8" spread="10.3"/>
                    <measurement group_id="B4" value="56.6" spread="9.6"/>
                    <measurement group_id="B5" value="53.7" spread="10.7"/>
                    <measurement group_id="B6" value="57.3" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="57"/>
                    <measurement group_id="B6" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram/square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="4.1"/>
                    <measurement group_id="B2" value="30.9" spread="3.8"/>
                    <measurement group_id="B3" value="31.5" spread="4.5"/>
                    <measurement group_id="B4" value="31.2" spread="4.3"/>
                    <measurement group_id="B5" value="31.2" spread="4.8"/>
                    <measurement group_id="B6" value="31.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline glycosylated hemoglobin (HbA1c)</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="0.63"/>
                    <measurement group_id="B2" value="8.2" spread="0.62"/>
                    <measurement group_id="B3" value="8.4" spread="0.80"/>
                    <measurement group_id="B4" value="8.4" spread="0.80"/>
                    <measurement group_id="B5" value="8.3" spread="0.64"/>
                    <measurement group_id="B6" value="8.3" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting blood plasma glucose (FPG)</title>
          <units>milligram/deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183.0" spread="34.9"/>
                    <measurement group_id="B2" value="185.2" spread="34.0"/>
                    <measurement group_id="B3" value="191.9" spread="37.8"/>
                    <measurement group_id="B4" value="188.7" spread="40.1"/>
                    <measurement group_id="B5" value="193.9" spread="45.9"/>
                    <measurement group_id="B6" value="188.4" spread="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12</title>
        <description>The change from baseline reflects the Week 12 HbA1c minus the Week 0 HbA1c. Means are adjusted for baseline HbA1c.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>Full Analysis Set includes all randomized patients with baseline and on-treatment value of HbA1c. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin (BI 1356) 0.5 mg</title>
            <description>Patients randomized to receive treatment with linagliptin 0.5 mg</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin (BI 1356) 2.5 mg</title>
            <description>Patients randomized to receive treatment with linagliptin 2.5 mg</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin (BI 1356) 5.0 mg</title>
            <description>Patients randomized to receive treatment with linagliptin 5.0 mg</description>
          </group>
          <group group_id="O5">
            <title>Metformin</title>
            <description>Patients randomized to receive treatment with metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12</title>
          <description>The change from baseline reflects the Week 12 HbA1c minus the Week 0 HbA1c. Means are adjusted for baseline HbA1c.</description>
          <population>Full Analysis Set includes all randomized patients with baseline and on-treatment value of HbA1c. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.10"/>
                    <measurement group_id="O2" value="0.04" spread="0.10"/>
                    <measurement group_id="O3" value="-0.24" spread="0.10"/>
                    <measurement group_id="O4" value="-0.28" spread="0.10"/>
                    <measurement group_id="O5" value="-0.68" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 0.5 mg versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3271</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as a fixed classification effect and baseline HbA1c as a linear covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 2.5 mg versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as a fixed classification effect and baseline HbA1c as a linear covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5.0 mg versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as a fixed classification effect and baseline HbA1c as a linear covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as a fixed classification effect and baseline HbA1c as a linear covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</title>
        <description>Change from baseline reflects the Week 12 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>Full Analysis Set includes all randomized patients with baseline and on-treatment value of HbA1c. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin (BI 1356) 0.5 mg</title>
            <description>Patients randomized to receive treatment with linagliptin 0.5 mg</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin (BI 1356) 2.5 mg</title>
            <description>Patients randomized to receive treatment with linagliptin 2.5 mg</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin (BI 1356) 5.0 mg</title>
            <description>Patients randomized to receive treatment with linagliptin 5.0 mg</description>
          </group>
          <group group_id="O5">
            <title>Metformin</title>
            <description>Patients randomized to receive treatment with metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</title>
          <description>Change from baseline reflects the Week 12 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG.</description>
          <population>Full Analysis Set includes all randomized patients with baseline and on-treatment value of HbA1c. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="4.4"/>
                    <measurement group_id="O2" value="6.69" spread="4.6"/>
                    <measurement group_id="O3" value="-15.2" spread="4.7"/>
                    <measurement group_id="O4" value="-9.09" spread="4.8"/>
                    <measurement group_id="O5" value="-30.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 0.5 mg versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7027</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as a fixed classification effect and baseline FPG as a linear covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10</ci_lower_limit>
            <ci_upper_limit>15.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 2.5 mg versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as a fixed classification effect and baseline FPG as a linear covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-19.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-32</ci_lower_limit>
            <ci_upper_limit>-6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5.0 mg versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0418</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as a fixed classification effect and baseline FPG as a linear covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-26</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as a fixed classification effect and baseline FPG as a linear covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-34.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-47</ci_lower_limit>
            <ci_upper_limit>-22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Absolute Efficacy Response (HbA1c &lt;= 7.0%) at 12 Weeks</title>
        <description>An absolute efficacy response is defined as HbA1c &lt;= 7.0% at 12 weeks. A non-response is defined as HbA1c &gt; 7.0% at 12 weeks.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>FAS patients with baseline HbA1c &gt; 7.0%. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin (BI 1356) 0.5 mg</title>
            <description>Patients randomized to receive treatment with linagliptin 0.5 mg</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin (BI 1356) 2.5 mg</title>
            <description>Patients randomized to receive treatment with linagliptin 2.5 mg</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin (BI 1356) 5.0 mg</title>
            <description>Patients randomized to receive treatment with linagliptin 5.0 mg</description>
          </group>
          <group group_id="O5">
            <title>Metformin</title>
            <description>Patients randomized to receive treatment with metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Absolute Efficacy Response (HbA1c &lt;= 7.0%) at 12 Weeks</title>
          <description>An absolute efficacy response is defined as HbA1c &lt;= 7.0% at 12 weeks. A non-response is defined as HbA1c &gt; 7.0% at 12 weeks.</description>
          <population>FAS patients with baseline HbA1c &gt; 7.0%. Non-completers were considered as failure imputation (NCF).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c &lt;= 7%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="10.5"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="11.1"/>
                    <measurement group_id="O5" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &gt; 7%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7"/>
                    <measurement group_id="O2" value="89.5"/>
                    <measurement group_id="O3" value="92.7"/>
                    <measurement group_id="O4" value="88.9"/>
                    <measurement group_id="O5" value="73.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 0.5 mg versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.413</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.735</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.464</ci_lower_limit>
            <ci_upper_limit>6.492</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 2.5 mg versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.842</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.157</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.275</ci_lower_limit>
            <ci_upper_limit>4.861</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5.0 mg versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.364</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.844</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.492</ci_lower_limit>
            <ci_upper_limit>6.910</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.224</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.648</ci_lower_limit>
            <ci_upper_limit>16.562</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study medication up to a period of 30 days after the last dose of study medication, an average of 106 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients randomized to receive treatment with matching placebo</description>
        </group>
        <group group_id="E2">
          <title>Linagliptin (BI 1356) 0.5 mg</title>
          <description>Patients randomized to receive treatment with linagliptin 0.5 mg</description>
        </group>
        <group group_id="E3">
          <title>Linagliptin (BI 1356) 2.5 mg</title>
          <description>Patients randomized to receive treatment with linagliptin 2.5 mg</description>
        </group>
        <group group_id="E4">
          <title>Linagliptin (BI 1356) 5.0 mg</title>
          <description>Patients randomized to receive treatment with linagliptin 5.0 mg</description>
        </group>
        <group group_id="E5">
          <title>Metformin</title>
          <description>Patients randomized to receive treatment with metformin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Obstructive chronic bronchitis with acute exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

